From GlobeNewswire: 2025-06-15 05:00:00

Results from the EPCORE NHL-2 trial showed that the investigational treatment with epcoritamab in combination with R-ICE led to an 87% overall response rate and a 65% complete response rate in patients with relapsed or refractory DLBCL. The data was presented at the 30th European Hematology Association Congress. The safety profile of the combination therapy was favorable, with low-grade cytokine release syndrome and no treatment discontinuations due to adverse events. This new treatment option offers high response rates and a potential bridge to autologous stem cell transplantation for patients with relapsed or refractory DLBCL.



Read more at GlobeNewswire: Genmab Announces Epcoritamab Investigational Combination